New businesses aimed at solving social issues, including digital transformation in nursing care and healthcare
First written in FY2023. 2 of 5 entries say "Advanced", first in FY2024. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「R&D expenses for the current fiscal year were ¥18 million, and the main R&D activities were as follows: 1. In the occupational health field, planning and validation of support services to promote wellbeing; 2. In the nursing-care field, where challenges are increasing as the population ages, planning and validation of support services using IT; and 3. In other fields, planning and promotion of new businesses aimed at addressing social issues.」
For new businesses addressing social issues, the Company recognised ¥18 million in R&D expenses and expanded its focus from nursing care and healthcare DX to planning and validation of support for occupational health and wellbeing, as well as nursing care support. - FY2025-H1No R&D activities during the interim periodAnnual report
「(5) Research and development activities There were no applicable matters.」
The Company states that there were no applicable R&D activities during the interim consolidated accounting period. It does not state that the initiatives in nursing care and healthcare DX presented in the previous fiscal year were withdrawn. - FY2024AdvancedAnnual report
「R&D expenses for the current fiscal year were ¥19 million, and the main R&D activities were as follows: 1. In the nursing-care field, where challenges are increasing as the population ages, planning and demonstration testing of support services, including IT-based support for facility operations; 2. In the healthcare field, where digitalisation is lagging, planning and demonstration testing of administrative support services to promote healthcare DX; and 3. In other fields, planning and promotion of new businesses aimed at addressing social issues.」
Although no R&D activities were disclosed for the previous quarter, the Company recognised ¥19 million in full-year R&D expenses and continued planning and demonstration testing for nursing-care support, healthcare DX and other new businesses addressing social issues. - FY2024-Q3No R&D activities disclosed for the quarterAnnual report
「None.」
The R&D activities section states that there were no applicable matters for the nine months ended the third quarter of the current fiscal year. It does not state that the R&D initiatives in nursing care and healthcare DX presented in the previous fiscal year were withdrawn. - FY2023First statedAnnual report
「As a medium- to long-term initiative supporting sustainable growth, the Group worked to create new businesses aimed at addressing social issues. R&D expenses for the current fiscal year were ¥25 million, and the main R&D activities were as follows: 1. In the nursing-care field, where challenges are increasing as the population ages, planning and demonstration testing of support services, including IT-based support for facility operations; 2. In the healthcare field, where digitalisation is lagging, planning and demonstration testing of administrative support services to promote healthcare DX; and 3. In other fields, planning and promotion of new businesses aimed at addressing social issues.」
The Group invested ¥25 million in R&D and is advancing the planning and demonstration testing of support for nursing-care facility operations, administrative support for healthcare DX, and other new businesses addressing social issues.